About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and Bispecifics
By
MyCancerHaven
FEATURING
Ravi Vij
,
Nitya Nathwani
By
MyCancerHaven
FEATURING
Ravi Vij
,
Nitya Nathwani
233 views
May 2, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
17:52
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
Feat.
K. Anderson
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
24:35
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …
Feat.
H. Hashmi
07:11
GRACE
CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…
Feat.
A. Goodman,
A. Jeong,
S. Rajeeve
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
24:23
MyCancerHaven
Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?
Feat.
R. Vij,
S. Al Hadidi
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
36:10
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
Feat.
S. Al Hadidi
35:27
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
Feat.
K. Anderson
13:47
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…
Feat.
B. Derman
20:23
SOHO Brazil 2024
When to Consider Bispecific and CAR-T Therapy in MM
Feat.
N. S. Raje
05:35
Saurabh Chhabra
Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence
26:46
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…
22:33
Integrity CE
Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy
Feat.
S. Usmani,
J. Hillengass
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
35:37
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
Feat.
D. Sherbenou
03:42
Moffitt Cancer Center
Multiple Myeloma: What You Need to Know About New FDA Approvals of C…
Feat.
D. Hansen
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
